Prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma

A. Riccardi, G. Ucci, S. Brugnatelli, O. Mora, G. Merlini, N. Piva, A. De Paoli, L. Barbarano, M. Di Stasi, F. Alberio, G. Nicoletti, S. Morandi, E. Rinaldi, L. Piccinini, E. Ascari

Research output: Contribution to journalArticlepeer-review

Abstract

Bone resorption by osteoclasts causes neoplastic one disease, which is a significant cause of death in multiple myeloma (MM). Counteracting bone resorption with prophylactic bisphosphonates has delayed bone disease, and this is expected to improve survival. Between January, 1987 and March, 1990, 341 evaluable previously untreated, consecutive patients with MM entered a prospective, multicenter study in which cytostatic therapy was randomized. The first 148 patients recruited were not planned for prophylaxis and the following 193 were scheduled to receive parenteral, prophylactic clodronate. Clodronate was administered at a dose of 600-1000 mg/4-6 weeks and was started at diagnosis and continued throughout survival time. Data on clodronate prophylaxis we{e evaluated on both an intention-to-treat and a compliance analysis basis. The rate of response and the duration of response were independent of clodronate prophylaxis. Progression of skeletal disease occurred less often in patients who received the drug than in those who were not given prophylaxis (50.5 vs 34.8%; p

Original languageEnglish
Pages (from-to)833-839
Number of pages7
JournalInternational Journal of Oncology
Volume5
Issue number4
Publication statusPublished - 1994

Keywords

  • Bisphosphonates
  • Bone disease
  • Bone disease prophylaxis
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma'. Together they form a unique fingerprint.

Cite this